Institutional investors purchased a net $524.8 thousand shares of MYGN during the quarter ended March 2018 and now own 110.08% of the total shares outstanding. This majority interest is a greater percentage than is typical for companies in the Biotechnology industry and highlights that the smart money sees this stock as an important holding.